Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Agenus Inc.

< Previous 1 2 Next >
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Tickers AGEN
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
From Agenus Inc.
Via Business Wire
Tickers AGEN
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Participate in September Investor Conferences
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Second Quarter 2024 Operational and Financial Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Appointment of Tom Harrison to Board of Directors
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
From Agenus Inc.
Via Business Wire
Tickers AGEN
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Tickers AGEN
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
From Agenus Inc.
Via Business Wire
Tickers AGEN
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports First Quarter 2024 Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Agenus Inc.
Via Business Wire
Tickers AGEN
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Reverse Stock Split of Common Stock
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Fourth Quarter and Full Year 2023 Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
From Agenus Inc.
Via Business Wire
Tickers AGEN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.